Guangzhou Sino-Israel Biotech Investment Fund (GIBF)

About

Portfolio · 7

Biond Biologics

Immunotherapies for Cancer and Auto-immune Diseases

Led ★ 1 round $8.0M committed Latest: 2026-06

Nectin Therapeutics

Next-generation Immunotherapy Agents

Led ★ 1 round $10.0M committed Latest: 2024-05

Kamari Pharma

Small Molecule Inhibitors of TRPV3

1 round $8.0M committed Latest: 2022-09

CoreBone

Bioactive Coral-based Bone Graft

Led ★ 1 round $3.7M committed Latest: 2021-10

CorNeat Vision

A new era of medical devices

Led ★ 1 round $4.0M committed Latest: 2021-08

Alpha Omega

Functional Neurosurgery and Neuroscience Research Solutions

1 round $7.0M committed Latest: 2018-12

Neurotech Solutions

AI-based Technology for Diagnosing ADHD

Led ★ 1 round $3.5M committed Latest: 2018-03

Investment activity

Funds · 2

• 2 — $300M May 2021
• 1 — $100M Mar 2016

Q&A

What is Guangzhou Sino-Israel Biotech Investment Fund (GIBF)'s primary investment focus?

GIBF focuses on drug development and delivery companies that are at clinical or approaching clinical stages of development and aspire to establish activities in China. Their investment range is typically $5-20 million per ticket.

When was GIBF established and what is its current fund status?

GIBF was established in 2016 and is currently investing out of its second fund, which has a size of $300 million. Their first fund, totaling $100 million, completed its investment period in 2021.

Which stages of investment does GIBF typically target?

GIBF targets Pre-Seed, Seed, and A Round investment stages.

Can you name some of GIBF's portfolio companies?

GIBF's portfolio includes companies such as Nectin Therapeutics, which raised $36 million in an A Round, and Kamari Pharma, which raised $31 million in an A Round.

What is the geographic focus of GIBF's headquarters?

GIBF's headquarters are located in Tel Aviv-Yafo, Israel.

Who are some of the key individuals on GIBF's leadership team?

The leadership team includes Dr. Yehoshua (Shuki) Gleitman as Chairman, Avner Lushi as CEO, and Prof. Shlomo Noy as Chief Medical Officer.

What is GIBF's sector concentration?

GIBF shows a strong concentration in the Health Tech & Life Sciences sector, with all six of its listed portfolio companies falling into this category.

What was the size of GIBF's first fund?

GIBF's first fund, established in March 2016, had an amount of $100 million.

When did GIBF raise its second fund and what was its size?

GIBF raised its second fund in May 2021, with an amount of $300 million.